News

6th MAY 2008

AMDIPHARM INTERNATIONAL LTD COMPLETES ACQUISITION OF SHIRE'S MAXOLON, BARATOL, HORMONIN, CELEVAC AND TOPICYCLINE

Amdipharm International has today announced the acquisition of a portfolio of products in several European territories from Shire Pharmaceuticals. The deal gives Amdipharm exclusive marketing rights for the following product lines:

UK

Maxolon

Hormonin

Celevac

Baratol

Topicycline

REPUBLIC OF IRELAND

Maxolon

Celevac

ITALY

Mecloderm

FRANCE

Veratran

Recognised for its young, dynamic and entrepreneurial personality, Amdipharm has garnered a significant level of growth and success since its inception in 2002 and is now widely considered a partner of choice with respect to both the acquisition and management of established brands. Already the company boasts a presence in over 100 countries and a portfolio of over 35 products. Sales in 2008 are projected to reach £120 million.

6th MAY 2008

AMDIPHARM ACQUIRES A PORTFOLIO OF BRANDS

Amdipharm is pleased to announce the acquisition of rights to a portfolio of 12 products in over 80 countries (Europe, Middle-East, Asia-Pacific and Africa) from Novartis.

The products acquired are:

Apresoline*

Hygroton

Hygroton Reserpine

Cafergot

Deseril

Dihydergot

Migranal

Tofranil

Ludiomil

Locacorten*

Locasalen*

Sicorten*

*Amdipharm previously acquired rights to these products in certain countries; the geographic range is now extended.

Sales of these products in the newly acquired countries were over US$45 million in 2007.

Commenting on the acquisition, Mick Cullen, Director of Amdipharm said “This latest acquisition significantly extends our geographic reach, as well as adding to our critical mass in a number of key territories”.

Founded by Vijay and Bhikhu Patel in 2002, Amdipharm has grown rapidly by the acquisition and management of established brands. Sales in 2008 are projected to reach £120M.

NOVEMBER 2007

Amdipharm International announces that it has acquired from F. Hoffmann - La Roche Ltd, the marketing rights in the UK and Republic of Ireland for the following products.

Gentisone HC Ear Drops

Genticin Injection

Genticin Ear/Eye Drops

“This acquisition adds to the Company’s rapidly growing branded product portfolio and complements our earlier acquisition of Locorten Vioform Ear Drops.” comments Roger Dickinson, Commercial Director of Amdipharm Plc.

Amdipharm has expanded rapidly since its inception in 2003, and considers itself a partner of choice in the acquisition and management of well established brands. The Company currently has products in over 80 countries with plans for further geographic expansion.